Patents Examined by Marsha Tsay
-
Patent number: 12023400Abstract: Disclosed herein is a recombinant protein including botulinum toxin and cell penetrating peptides and cosmetic composition. The cell penetrating peptide according to the present disclosure may be actively used as a topical agent for various disease treatment, aesthetic, or cosmetic purposes, especially for a cosmetic composition, by securing better convenience as well as maximizing the intrinsic in vivo efficacy of the botulinum toxin through the cell penetrating recombinant proteins that combines the botulinum toxin and a cell penetrating peptide by making skin penetration and/or cell penetration for botulinum toxin more efficient.Type: GrantFiled: May 7, 2021Date of Patent: July 2, 2024Assignee: Kan Zen Co., LtdInventors: Won Sup Choi, Hyun Sun Park, Da Som Kwon, Tae Kyu Park
-
Patent number: 12016956Abstract: The present invention relates to a lyophilizate comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. The present invention also relates to a composition comprising: a solution comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. Finally, the present invention relates to a process for preparing the lyophilizate.Type: GrantFiled: September 8, 2020Date of Patent: June 25, 2024Assignee: HemarinaInventors: Franck Zal, Morgane Rousselot
-
Patent number: 12018046Abstract: The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.Type: GrantFiled: April 11, 2022Date of Patent: June 25, 2024Assignee: Biogen MA Inc.Inventors: Austen Ng, Robert S. Gronke
-
Patent number: 12006526Abstract: The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG), or optionally MEG and one or more co-product, from one or more hexose feedstock. The present application also relates to recombinant microorganisms useful in the biosynthesis of glycolic acid (GA), or optionally GA and one or more co-product, from one or more hexose feedstock. The present application relates to recombinant microorganisms useful in the biosynthesis of xylitol, or optionally xylitol and one or more co-product, from one or more hexose feedstock. Also provided are methods of producing MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product, from one or more hexose feedstock using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or the products MEG (or GA or xylitol), or optionally MEG (or GA or xylitol) and one or more co-product.Type: GrantFiled: February 20, 2020Date of Patent: June 11, 2024Assignee: BRASKEM S.A.Inventors: Daniel Johannes Koch, Lucas Pedersen Parizzi, Felipe Galzerani
-
Patent number: 11987830Abstract: Provided herein are cell free protein synthesis (CFPS) systems comprising a plurality of ribosomes attached to or encapsulated within a structure, or a plurality of structures, and, optionally, a solid support. Also provided are related kits and uses of the CFPS systems. Methods of producing a protein and methods of treating a disease are provided herein.Type: GrantFiled: January 24, 2020Date of Patent: May 21, 2024Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLCInventors: Nicholas N. Watkins, Neil Reginald Beer, Kenneth W. Turteltaub
-
Patent number: 11965002Abstract: A light-activated construct composed of two photoreceptive polypeptide domains connected to one another by a flexible linker is provided, as is a fusion protein containing the same and polynucleotides encoding said construct and fusion protein. Methods of making and using the light-activated construct and fusion protein are also provided.Type: GrantFiled: November 29, 2019Date of Patent: April 23, 2024Assignee: THE BD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Andrei Karginov
-
Patent number: 11959116Abstract: The present invention addresses the problem of providing a method for producing nicotinamide mononucleotide, that produces nicotinamide mononucleotide using a single enzyme and using nucleoside monophosphate, pyrophosphate, and nicotinamide as starting materials. This problem is solved by a nicotinamide mononucleotide production method that includes at least the following steps 1) and 2): 1) a first step of producing phosphoribosyl diphosphate by the action of substantially one enzyme on nucleoside monophosphate and pyrophosphate; and 2) a second step of producing nicotinamide mononucleotide by the action of only substantially the aforementioned one enzyme on nicotinamide and the phosphoribosyl diphosphate that is the product of the first step.Type: GrantFiled: October 26, 2022Date of Patent: April 16, 2024Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Takeshi Matsuoka, Tatsuya Hirata, Masaru Yamakoshi
-
Patent number: 11957324Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.Type: GrantFiled: May 12, 2021Date of Patent: April 16, 2024Assignees: Ethicon, Inc., Omrix Biopharmaceuticals, Ltd.Inventors: Ashley DeAnglis, Yair Pilpel, Yuri Zherdev, Sivan Doron, Lior Erez
-
Patent number: 11959121Abstract: The invention relates to the detection of the cofactor reduced nicotinamide adenine dinucleotide phosphate (NADPH). Provided is a sensor molecule for the resonance energy transfer (RET)-based detection of NADPH, the sensor comprising a segment A connected via a linker to a segment B, wherein each of segment A and segment B comprises a member of a RET pair comprising a donor moiety and an acceptor moiety, further characterized in that (i) segment A comprises a binding protein (BP) for NADPH, the BP being dihydrofolate reductase (DHFR; EC 1.5.1.3) or a functional homolog, fragment, derivative or variant thereof, showing the desired NADPH binding properties, and wherein the BP comprises a heterologous protein domain inserted at or replacing at least part of the region corresponding to positions (20) to (27) of E.Type: GrantFiled: May 29, 2018Date of Patent: April 16, 2024Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Qiuliyang Yu, Kai Peter Johnsson
-
Patent number: 11952601Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: GrantFiled: June 20, 2017Date of Patent: April 9, 2024Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Patent number: 11945847Abstract: The present disclosure relates to compounds, compositions, and methods for the inducing neurodegenerative disease pathologies. In one aspect, disclosed herein is a nucleotide sequence encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease in target protein. Disclosed herein is a method of inducing a neurodegenerative disease pathology in a cell, comprising the steps: introducing into the cell an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter; expressing the chimeric polypeptide; and inducing oligomerization of the chimeric polypeptide by stimulation with blue light.Type: GrantFiled: March 7, 2018Date of Patent: April 2, 2024Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Christopher James Donnelly, Jacob R. Mann
-
Patent number: 11918632Abstract: The present invention provides a method for preventing or treating liver cancer in a subject comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide and an expression vector containing the polynucleotide to the subject.Type: GrantFiled: July 25, 2022Date of Patent: March 5, 2024Assignees: CUROGEN TECHNOLOGY CO., LTD., RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITYInventors: Chang Woo Lee, Jin Kwan Lee, Hyun Soo Kim, Jae-kyung Kim, Joon Sup Yoon
-
Patent number: 11912746Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: GrantFiled: May 6, 2022Date of Patent: February 27, 2024Assignee: 2seventy bio, Inc.Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
-
Patent number: 11884705Abstract: Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin ? chain binding activity.Type: GrantFiled: September 25, 2018Date of Patent: January 30, 2024Assignees: JSR CORPORATION, JSR Life Sciences Corporation, JSR Life Sciences, LLC, JSR Micro N.V.Inventors: Jun-ichi Yasuoka, Kiichi Yoshimura, Tomoaki Haga
-
Patent number: 11866714Abstract: A promoter operably linked to a gene encoding a protein is disclosed. The promoter drives expression of the protein in a yeast cell in the absence of methanol. Also disclosed are vectors, host cells and expression systems that include the promoter, as well as methods of using the promoter to express proteins in yeast.Type: GrantFiled: June 3, 2019Date of Patent: January 9, 2024Assignee: BASF SEInventors: Xuqiu Tan, Ruorong Cai, Jingping Zhong, Melissa Ann Scranton, Michael Speer
-
Patent number: 11867685Abstract: The invention relates to the identification of OR5A2 as an Olfactory Receptor that binds natural musk and synthetic musks. The invention encompasses the use of the interaction of OR5A2 polypeptides and nitromusk, polycyclic musk, macrocyclic musk and alicyclic musks as the basis of screening assays for agents that specifically modulate the activity of the OR of the invention.Type: GrantFiled: December 5, 2018Date of Patent: January 9, 2024Assignee: CHEMCOM S.A.Inventors: Sandra Huysseune, Alex Veithen, Yannick Quesnel
-
Patent number: 11859190Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.Type: GrantFiled: March 3, 2021Date of Patent: January 2, 2024Assignee: Sangamo Therapeutics, Inc.Inventor: Edward J. Rebar
-
Patent number: 11851666Abstract: The present invention belongs to the field of biotechnology, specifically to the field of recombinant protein expression. The present invention focuses on two problems commonly encountered during recombinant protein expression, low quantity of protein expression and genetic instability of cell lines used for recombinant protein expression. The basic principle of the present invention is to introduce several expression cassettes into a cell which expression cassettes all code for the same mature recombinant protein of interest, but which expression cassettes have different nucleotide sequences. Expression cassette means a polynucleotide sequence which comprises at least a promoter sequence, a start codon, a polynucleotide sequence coding for a protein which is intended to be recombinant expressed (POI), a stop codon and a terminator.Type: GrantFiled: August 22, 2018Date of Patent: December 26, 2023Inventors: Clemens Achmüller, Norbert Lamping, Matjaz Vogelsang
-
Patent number: 11845780Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.Type: GrantFiled: December 1, 2020Date of Patent: December 19, 2023Assignee: Oxford Nanopore Technologies PLCInventors: Mark Bruce, James Anthony Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace
-
Patent number: 11834479Abstract: Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.Type: GrantFiled: April 3, 2020Date of Patent: December 5, 2023Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Floyd E. Romesberg, Yorke Zhang